Palvella Shares Rally After SELVA Phase 3 Shows Statistically Significant Benefits for QTORIN 3.9% Gel
Palvella Therapeutics shares climbed 15% after the company reported positive topline results from its Phase 3 SELVA trial of QTORIN 3.9% rapamycin anhydrous gel for microcystic lymphatic malformations. The study met its primary endpoint and a pre-specified key secondary endpoint with strong statistical significance, showed favorable tolerability an…